INC Research(R) Appoints Hans J. Moebius as Senior Vice President of CNS Division for Europe

INC Research(R), a therapeutically focused contract research
organization with a trusted process for delivering reliable results,
has named Hans J. Moebius, M.D., Ph.D., as Senior Vice President of
its central nervous system (CNS) business for Europe. In this
position, Dr. Moebius will be responsible for the operations,
strategic planning and corporate development of INC Research's
European CNS business and will have management oversight for all CNS
and Pediatrics research staff and clinical trials taking place in
Europe.

Dr. Moebius will also oversee INC Research's expansion into
Switzerland and will serve as head of the INC Research Zurich office,
which opens in January 2007. Dr. Moebius has more than 16 years of
strategic drug development experience in Europe, the United States and
Japan and has personally overseen the development of NCEs in epilepsy,
Parkinson's disease, depression, Alzheimer's disease and vascular
dementia, ADHD, spasticity, neuropathic pain, chronic pain, and
addiction. He has worked with the FDA, EMEA and several national
authorities for the successful registration of five new CNS therapies
including all aspects of pre-clinical and clinical development,
regulatory strategy and establishing global pharmacovigilance
strategies. Dr. Moebius will play a leading role in INC's Product
Development Services (PDS) group providing CNS drug development
consultancy to INC's pharmaceutical customers.

"Dr. Moebius is an exceptional addition to our international CNS
team," said Kelvin Logan, Ph.D., President of INC Research, Europe.
"As we look to further solidify and expand our presence within the
European CRO market, Dr. Moebius' substantial clinical and management
expertise will be extremely beneficial in continuing to establish INC
Research as an industry leader globally."

Before joining INC Research, Dr. Moebius served for 10 years with
Merz Pharmaceuticals, for the last five years as Chief Scientific
Officer and Managing Director. He was responsible for the supervision
of seven different departments and hundreds of employees, establishing
the company's CNS drug development pipeline and managing international
drug development programs and partnerships. Prior to that, he served
for five years as senior vice president, global research and
development and drug regulatory affairs.

Dr. Moebius has won a number of professional distinctions,
including heading up the team that won the German Industry Innovation
Award for the international development of memantine in late-stage
Alzheimer's disease (2002).

He is currently a member of the European College of
Neuropsychopharmacology, the German Society of Pharmaceutical
Physicians, the American Academy of Neurology and the German Society
for Neurology. He has participated in the international working group
for the development of anti-dementia guidelines and is a founding
member of the American Society for Experimental Neurotherapeutics and
the Swiss Association of Pharmaceutical Physicians.

Dr. Moebius earned a bachelor's of science degree in chemistry
from the University of Kaiserslautern and a doctorate degree in
experimental pharmacology from the University of Heidelberg. He is a
board certified psychiatrist and neurologist who completed his medical
studies at the Universities of Heidelberg and Frankfurt in Germany. He
holds the Swiss Degree in Pharmaceutical Medicine.

About INC Research(R)

INC Research is a therapeutically focused contract research
organization with an unrivaled reputation for conducting global
clinical development programs of the highest integrity. Pharmaceutical
and biotechnology companies look to INC Research for a complete range
of customized Phase 1 - Phase 4 programs in therapeutic areas of
specialty, and in innovative pediatric trials. Our "Trusted
Process(TM)" methodology and therapeutic foresight leads our customers
to more confident, better-informed drug and device development
decisions. INC Research is headquartered in Raleigh, North Carolina,
and in 21 locations in 30 countries worldwide. For more information,
please visit our website at www.incresearch.com.